144 related articles for article (PubMed ID: 38399618)
1. Comparison of Integrase Strand Transfer Inhibitors (INSTIs) and Protease-Boosted Inhibitors (PIs) on the Reduction in Chronic Immune Activation in a Virally Suppressed, Mainly Male Population Living with HIV (PLWH).
Nitsotolis T; Kyriakoulis KG; Kollias A; Papalexandrou A; Kalampoka H; Mastrogianni E; Basoulis D; Psichogiou M
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399618
[No Abstract] [Full Text] [Related]
2. Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis.
Gianella S; Letendre SL; Iudicello J; Franklin D; Gaufin T; Zhang Y; Porrachia M; Vargas-Meneses M; Ellis RJ; Finkelman M; Hoenigl M
J Neurovirol; 2019 Dec; 25(6):837-843. PubMed ID: 31297727
[TBL] [Abstract][Full Text] [Related]
3. Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.
O'Halloran JA; Cooley SA; Strain JF; Boerwinkle A; Paul R; Presti RM; Ances BM
AIDS; 2019 Jul; 33(9):1477-1483. PubMed ID: 31008801
[TBL] [Abstract][Full Text] [Related]
4. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
6. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
Han WM; Kerr SJ; Avihingsanon A; Boettiger DC
J Antimicrob Chemother; 2022 Nov; 77(12):3242-3247. PubMed ID: 36101517
[TBL] [Abstract][Full Text] [Related]
7. The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Quiros-Roldan E; Castelli F; Bonito A; Vezzoli M; Calza S; Biasiotto G; Zanella I;
Cytokine; 2020 Feb; 126():154884. PubMed ID: 31670006
[TBL] [Abstract][Full Text] [Related]
8. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study.
Lao X; Zhang H; Deng M; Li Q; Xiao Q; He L; Ma L; Song A; Liang X; Yu F; Zhao H; Zhang F
BMC Infect Dis; 2024 Jan; 24(1):8. PubMed ID: 38166689
[TBL] [Abstract][Full Text] [Related]
9. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients.
Villanueva-Millán MJ; Pérez-Matute P; Recio-Fernández E; Lezana Rosales JM; Oteo JA
J Int AIDS Soc; 2017 Mar; 20(1):21526. PubMed ID: 28362071
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
[TBL] [Abstract][Full Text] [Related]
12. Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
Peterson TE; Landon C; Haberlen SA; Bhondoekhan F; Plankey MW; Palella FJ; Piggott DA; Margolick JB; Brown TT; Post WS; Wu KC
BMC Cardiovasc Disord; 2022 Sep; 22(1):393. PubMed ID: 36057773
[TBL] [Abstract][Full Text] [Related]
13. Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan.
Naito T; Mori H; Fujibayashi K; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Suzuki M; Goto-Hirano K; Kuwatsuru R
Sci Rep; 2022 Feb; 12(1):1732. PubMed ID: 35110641
[TBL] [Abstract][Full Text] [Related]
14. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
15. HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation.
Monnig MA; Cohen R; Ramratnam B; McAdams M; Tashima K; Monti PM
Alcohol Clin Exp Res; 2019 Jun; 43(6):1126-1134. PubMed ID: 30908642
[TBL] [Abstract][Full Text] [Related]
16. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
[TBL] [Abstract][Full Text] [Related]
17. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
[TBL] [Abstract][Full Text] [Related]
18. Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China.
Lai J; Liu Y; Han X; Huang A; Lin J; Ao W; Ye H; Chen Y
Drug Des Devel Ther; 2021; 15():889-894. PubMed ID: 33679129
[TBL] [Abstract][Full Text] [Related]
19. Cocaine use associated gut permeability and microbial translocation in people living with HIV in the Miami Adult Study on HIV (MASH) cohort.
Hernandez J; Tamargo JA; Sales Martinez S; Martin HR; Campa A; Sékaly RP; Bordi R; Sherman KE; Rouster SD; Meeds HL; Khalsa JH; Mandler RN; Lai S; Baum MK
PLoS One; 2022; 17(10):e0275675. PubMed ID: 36215260
[TBL] [Abstract][Full Text] [Related]
20. Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study.
Haddaji A; Ouladlahsen A; Lkhider M; Bensghir R; Jebbar S; Hilmi S; Abbadi I; Sodqi M; Marih L; Pineau P; El Filali KM; Ezzikouri S
Arch Microbiol; 2023 May; 205(6):223. PubMed ID: 37154966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
